[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hemoglobinopathy":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":85,"states":86},"Hemoglobinopathy",12,11,[8,15,22,29,35,42,48,54,60,66,72,78],{"nct_id":9,"title":10,"phases":11,"status":12,"updated_at":13,"content_modified":14},"NCT01666080","Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)",[],"RECRUITING","2026-08-26T02:19:02.550788Z","2026-05-05T02:43:28.871503Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT02356653","Expanded Access Protocol Using CD3+\u002FCD19+ Depleted PBSC",[19],"Early Phase 1","2026-08-26T02:16:08.402952Z","2026-05-05T02:43:29.132129Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT06839456","Phase 1\u002F2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab\u002FCD19 Depleted HSCT",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:26.932189Z","2026-05-05T02:43:28.655842Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT00920972","Campath\u002FFludarabine\u002FMelphalan Transplant Conditioning for Non-Malignant Diseases",[26],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.017972Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":40,"content_modified":41},"NCT04644016","Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders",[39],"Phase 2","2026-08-26T02:16:48.735701Z","2026-05-05T02:43:27.256850Z",{"nct_id":43,"title":44,"phases":45,"status":12,"updated_at":46,"content_modified":47},"NCT03128996","Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders",[26],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:26.748524Z",{"nct_id":49,"title":50,"phases":51,"status":12,"updated_at":52,"content_modified":53},"NCT06646640","Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy",[],"2026-08-26T02:15:13.282904Z","2026-05-13T02:55:06.558200Z",{"nct_id":55,"title":56,"phases":57,"status":12,"updated_at":58,"content_modified":59},"NCT05799118","Study of the Role of Genetic Modifiers in Hemoglobinopathies",[],"2026-08-26T02:18:34.622081Z","2026-05-13T02:55:06.377334Z",{"nct_id":61,"title":62,"phases":63,"status":12,"updated_at":64,"content_modified":65},"NCT04671212","Discarded Bone Marrow for Hematology Research",[],"2026-08-26T02:19:17.380174Z","2026-05-13T02:55:06.258466Z",{"nct_id":67,"title":68,"phases":69,"status":12,"updated_at":70,"content_modified":71},"NCT06313398","Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling",[19],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:26.955670Z",{"nct_id":73,"title":74,"phases":75,"status":12,"updated_at":76,"content_modified":77},"NCT06872333","Allo HSCT for High Risk Hemoglobinopathies",[39],"2026-08-26T02:18:51.833592Z","2026-07-05T05:32:16.699778Z",{"nct_id":79,"title":80,"phases":81,"status":82,"updated_at":83,"content_modified":84},"NCT07660783","Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases",[39],"NOT_YET_RECRUITING","2026-08-26T02:17:16.980188Z","2026-07-05T03:45:20.258362Z",[],[87],{"state":88,"count":89,"slug":90},"Pennsylvania",3,"pennsylvania"]